Patents by Inventor Jun Kurosaka

Jun Kurosaka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • C-4? position substituted macrolide derivative
    Patent number: 9139609
    Abstract: A macrolide compound represented by the formula (I) effective against erythromycin resistant bacteria (for example, resistant pneumococci, streptococci and mycoplasmas).
    Type: Grant
    Filed: February 20, 2012
    Date of Patent: September 22, 2015
    Assignees: TAISHO PHARMACEUTICAL CO., LTD., MEIJI SEIKA PHARMA CO., LTD.
    Inventors: Tomohiro Sugimoto, Naoki Sasamoto, Jun Kurosaka, Masato Hayashi, Kanako Yamamoto, Masato Kashimura, Yasunobu Ushiki, Haruhisa Ogita, Tomoaki Miura, Kenichi Kanemoto, Kou Kumura, Satoshi Yoshida, Keiji Tamura, Eiki Shitara
  • C-4" POSITION SUBSTITUTED MACROLIDE DERIVATIVE
    Publication number: 20140046043
    Abstract: A macrolide compound represented by the formula (I) effective against erythromycin resistant bacteria (for example, resistant pneumococci, streptococci and mycoplasmas).
    Type: Application
    Filed: February 20, 2012
    Publication date: February 13, 2014
    Applicants: MEIJI SEIKA PHARMA CO., LTD., TAISHO PHARMACEUTICAL CO., LTD.
    Inventors: Tomohiro Sugimoto, Naoki Sasamoto, Jun Kurosaka, Masato Hayashi, Kanako Yamamoto, Masato Kashimura, Yasunobu Ushiki, Haruhisa Ogita, Tomoaki Miura, Kenichi Kanemoto, Kou Kumura, Satoshi Yoshida, Keiji Tamura, Eiki Shitara
  • 10a-azalide compound having 4-membered ring structure
    Patent number: 8299035
    Abstract: A 10a-azalide compound having a 4-membered ring structure crosslinked at the 10a- and 12-positions, which is represented by the formula (I), and is effective on even Haemophilus influenzae, or erythromycin resistant bacteria (e.g., resistant pneunococci and streptococci).
    Type: Grant
    Filed: May 15, 2009
    Date of Patent: October 30, 2012
    Assignees: Taisho Pharmaceutucal Co., Ltd., Meiji Seika Pharma Co., Ltd.
    Inventors: Tomohiro Sugimoto, Kanako Yamamoto, Jun Kurosaka, Naoki Sasamoto, Masato Kashimura, Tomoaki Miura, Kenichi Kanemoto, Satoshi Yoshida, Kou Kumura, Keiichi Ajito
  • 10a-Azalide compound crosslinked at 10a- and 12-positions
    Patent number: 8293715
    Abstract: A novel 10a-azalide compound crosslinked at the 10a- and 12-positions, which is represented by the following formula, and is effective on even Hemophilus influenzae, or erythromycin resistant bacteria (e.g., resistant pneumococci and streptococci).
    Type: Grant
    Filed: August 6, 2008
    Date of Patent: October 23, 2012
    Assignees: Taisho Pharmaceutical Co., Ltd., Meiji Seika Pharma Co., Ltd.
    Inventors: Tomohiro Sugimoto, Kanako Yamamoto, Jun Kurosaka, Naoki Sasamoto, Masato Kashimura, Tomoaki Miura, Kenichi Kanemoto, Tomohiro Ozawa, Ken Chikauchi, Eiki Shitara
  • 10a-Azalide compound
    Patent number: 8097708
    Abstract: [Object]: To provide a compound having a novel structure effective against Hemophilus influenzae and erythromycin resistant bacteria (for example, resistant pneumococci and streptococci) as well as against conventional erythromycin sensitive bacteria. [Solution]: A novel 10a-azalide compound represented by the formula (I), a pharmaceutically acceptable salt thereof or a solvate thereof, or an intermediate for the preparation of the same. The compound of the present invention has superior antibacterial activity against Hemophilus influenzae, erythromycin resistant pneumococci and the like, and therefore, the compound can be used as a therapeutic agent of infectious diseases.
    Type: Grant
    Filed: February 7, 2007
    Date of Patent: January 17, 2012
    Assignees: Taisho Pharmaceutical Co., Ltd., Meiji Seika Kaisha, Ltd.
    Inventors: Tomohiro Sugimoto, Kanako Yamamoto, Akira Manaka, Haruhisa Ogita, Jun Kurosaka, Madoka Kawamura, Masato Kashimura, Naoki Sasamoto, Tomoaki Miura, Kenichi Kanemoto, Tomohiro Ozawa, Ken Chikauchi, Eiki Shitara, Dai Kubota
  • 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS
    Publication number: 20110237784
    Abstract: A novel 10a-azalide compound crosslinked at the 10a- and 12-positions, which is represented by the following formula, and is effective on even Hemophilus influenzae, or erythromycin resistant bacteria (e.g., resistant pneumococci and streptococci).
    Type: Application
    Filed: August 6, 2008
    Publication date: September 29, 2011
    Applicants: TAISHO PHARMACEUTICAL CO., LTD., MEIJI SEIKA KAISHA, LTD.
    Inventors: Tomohiro Sugimoto, Kanako Yamamoto, Jun Kurosaka, Naoki Sasamoto, Masato Kashimura, Tomoaki Miura, Kenichi Kanemoto, Tomohiro Ozawa, Ken Chikauchi, Eiki Shitara
  • 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE
    Publication number: 20110152239
    Abstract: The present invention relates to a process for preparing compositions of high concentrations of omega-3 fatty acids from krill. Furthermore, the invention relates to a composition comprising high concentrations of omega-3 fatty acids, and a lipid fraction from krill comprising high amounts of the fatty acids with chain length C14 and C 16.
    Type: Application
    Filed: May 15, 2009
    Publication date: June 23, 2011
    Applicants: TAISHO PHARMACEUTICAL CO., LTD., MEIJI SEIKA KAISHA, LTD.
    Inventors: Tomohiro Sugimoto, Kanako Yamamoto, Jun Kurosaka, Naoki Sasamoto, Masato Kashimura, Tomoaki Miura, Kenichi Kanemoto, Satoshi Yoshida, Kou Kumura, Keiichi Ajito
  • 10a-Azalide Compound
    Publication number: 20090281292
    Abstract: [Object]: To provide a compound having a novel structure effective against Hemophilus influenzae and erythromycin resistant bacteria (for example, resistant pneumococci and streptococci) as well as against conventional erythromycin sensitive bacteria. [Solution]: A novel 10a-azalide compound represented by the formula (I), a pharmaceutically acceptable salt thereof or a solvate thereof, or an intermediate for the preparation of the same. The compound of the present invention has superior antibacterial activity against Hemophilus influenzae, erythromycin resistant pneumococci and the like, and therefore, the compound can be used as a therapeutic agent of infectious diseases.
    Type: Application
    Filed: February 7, 2007
    Publication date: November 12, 2009
    Inventors: Tomohiro Sugimoto, Kanako Yamamoto, Akira Manaka, Haruhisa Ogita, Jun Kurosaka, Madoka Kawamura, Masato Kashimura, Naoki Sasamoto, Tomoaki Miura, Kenichi Kanemoto, Tomohiro Ozawa, Ken Chikauchi, Eiki Shitara, Dai Kubota